{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:48:34Z","timestamp":1760550514614,"version":"3.41.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,3,21]],"date-time":"2018-03-21T00:00:00Z","timestamp":1521590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s00280-018-3562-3","type":"journal-article","created":{"date-parts":[[2018,3,21]],"date-time":"2018-03-21T07:57:56Z","timestamp":1521619076000},"page":"897-909","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors"],"prefix":"10.1007","volume":"81","author":[{"given":"Sherwin K. B.","family":"Sy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yen Lin","family":"Chia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toufigh","family":"Gordi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ute","family":"Hoch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Eldon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,21]]},"reference":[{"issue":"4","key":"3562_CR1","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2165\/00003088-199733040-00001","volume":"33","author":"GG Chabot","year":"1997","unstructured":"Chabot GG (1997) Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet 33(4):245\u2013259. https:\/\/doi.org\/10.2165\/00003088-199733040-00001","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"3562_CR2","first-page":"2182","volume":"7","author":"RH Mathijssen","year":"2001","unstructured":"Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, Sparreboom A (2001) Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 7(8):2182\u20132194","journal-title":"Clin Cancer Res"},{"issue":"11","key":"3562_CR3","first-page":"2747","volume":"4","author":"A Sparreboom","year":"1998","unstructured":"Sparreboom A, de Jonge MJ, de Bruijn P, Brouwer E, Nooter K, Loos WJ, van Alphen RJ, Mathijssen RH, Stoter G, Verweij J (1998) Irinotecan (CPT-11) metabolism and disposition in cancer patients. Clin Cancer Res 4(11):2747\u20132754","journal-title":"Clin Cancer Res"},{"issue":"4","key":"3562_CR4","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0090-9556(24)15060-X","volume":"28","author":"JG Slatter","year":"2000","unstructured":"Slatter JG, Schaaf LJ, Sams JP, Feenstra KL, Johnson MG, Bombardt PA, Cathcart KS, Verburg MT, Pearson LK, Compton LD, Miller LL, Baker DS, Pesheck CV, Lord RS 3rd (2000) Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients. Drug Metab Dispos 28(4):423\u2013433","journal-title":"Drug Metab Dispos"},{"issue":"15","key":"3562_CR5","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1200\/JCO.2002.11.073","volume":"20","author":"R Xie","year":"2002","unstructured":"Xie R, Mathijssen RH, Sparreboom A, Verweij J, Karlsson MO (2002) Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis. J Clin Oncol 20(15):3293\u20133301","journal-title":"J Clin Oncol"},{"issue":"16","key":"3562_CR6","first-page":"4187","volume":"51","author":"Y Kawato","year":"1991","unstructured":"Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K (1991) Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51(16):4187\u20134191","journal-title":"Cancer Res"},{"issue":"5","key":"3562_CR7","first-page":"2012","volume":"6","author":"A Santos","year":"2000","unstructured":"Santos A, Zanetta S, Cresteil T, Deroussent A, Pein F, Raymond E, Vernillet L, Risse ML, Boige V, Gouyette A, Vassal G (2000) Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin Cancer Res 6(5):2012\u20132020","journal-title":"Clin Cancer Res"},{"issue":"6","key":"3562_CR8","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/j.1349-7006.2004.tb03245.x","volume":"95","author":"M Shingyoji","year":"2004","unstructured":"Shingyoji M, Takiguchi Y, Watanabe-Uruma R, Asaka-Amano Y, Matsubara H, Kurosu K, Kasahara Y, Tanabe N, Tatsumi K, Kuriyama T (2004) In vitro conversion of irinotecan to SN-38 in human plasma. Cancer Sci 95(6):537\u2013540","journal-title":"Cancer Sci"},{"issue":"6","key":"3562_CR9","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s00280-014-2577-7","volume":"74","author":"U Hoch","year":"2014","unstructured":"Hoch U, Staschen CM, Johnson RK, Eldon MA (2014) Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models. Cancer Chemother Pharmacol 74(6):1125\u20131137. https:\/\/doi.org\/10.1007\/s00280-014-2577-7","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"3562_CR10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00280-016-3192-6","volume":"79","author":"SK Sy","year":"2017","unstructured":"Sy SK, Sweeney TD, Ji C, Hoch U, Eldon MA (2017) Etirinotecan pegol administration is associated with lower incidences of neutropenia compared to irinotecan administration. Cancer Chemother Pharmacol 79(1):57\u201367. https:\/\/doi.org\/10.1007\/s00280-016-3192-6","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"3562_CR11","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1158\/1078-0432.CCR-12-1201","volume":"19","author":"GS Jameson","year":"2013","unstructured":"Jameson GS, Hamm JT, Weiss GJ, Alemany C, Anthony S, Basche M, Ramanathan RK, Borad MJ, Tibes R, Cohn A, Hinshaw I, Jotte R, Rosen LS, Hoch U, Eldon MA, Medve R, Schroeder K, White E, Von Hoff DD (2013) A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors. Clin Cancer Res 19(1):268\u2013278. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-1201","journal-title":"Clin Cancer Res"},{"key":"3562_CR12","unstructured":"ClinicalTrials.gov (2008) A phase 2a\/2b multicenter, open-label study to evaluate NKTR 102 in combination with cetuximab versus irinotecan in combination with cetuximab in second line colorectal cancer patients. Identifier NCT00598975, National Library of Medicine (US), Bethesda, MD. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00598975?term=NCT00598975&recrs=e&rank=1"},{"key":"3562_CR13","unstructured":"Lilly Bristol-Myers-Squibb (2004) Cetuximab (Erbitux package insert). http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/125084s225lbl.pdf . Accessed 23 Jan 2017"},{"key":"3562_CR14","doi-asserted-by":"crossref","unstructured":"Eldon M, Hoch U (2011) Population pharmacokinetics of NKTR-102, a topoisomerase I inhibitor-polymer conjugate, in patients with advanced solid tumors. J Clin Oncol 29 (15):Abstr 2598","DOI":"10.1200\/jco.2011.29.15_suppl.2598"},{"issue":"2","key":"3562_CR15","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO (2011) Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 13(2):143\u2013151. https:\/\/doi.org\/10.1208\/s12248-011-9255-z","journal-title":"AAPS J"},{"issue":"10","key":"3562_CR16","doi-asserted-by":"publisher","first-page":"6242","DOI":"10.1128\/AAC.03073-14","volume":"58","author":"L Kock de","year":"2014","unstructured":"de Kock L, Sy SK, Rosenkranz B, Diacon AH, Prescott K, Hernandez KR, Yu M, Derendorf H, Donald PR (2014) Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis. Antimicrob Agents Chemother 58(10):6242\u20136250. https:\/\/doi.org\/10.1128\/AAC.03073-14","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"3562_CR17","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1128\/AAC.04049-14","volume":"59","author":"SK Sy","year":"2015","unstructured":"Sy SK, de Kock L, Diacon AH, Werely CJ, Xia H, Rosenkranz B, van der Merwe L, Donald PR (2015) N-acetyltransferase genotypes and the pharmacokinetics and tolerability of para-aminosalicylic acid in patients with drug-resistant pulmonary tuberculosis. Antimicrob Agents Chemother 59(7):4129\u20134138. https:\/\/doi.org\/10.1128\/AAC.04049-14","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"3562_CR18","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, Ckd EPI (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604\u2013612","journal-title":"Ann Intern Med"},{"issue":"7","key":"3562_CR19","doi-asserted-by":"publisher","first-page":"4128","DOI":"10.1128\/AAC.03099-15","volume":"60","author":"J Albiero","year":"2016","unstructured":"Albiero J, Sy SK, Mazucheli J, Caparroz-Assef SM, Costa BB, Alves JL, Gales AC, Tognim MC (2016) Pharmacodynamic evaluation of the potential clinical utility of fosfomycin and meropenem in combination therapy against KPC-2-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 60(7):4128\u20134139. https:\/\/doi.org\/10.1128\/AAC.03099-15","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"3562_CR20","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1023\/A:1011579109640","volume":"28","author":"KG Kowalski","year":"2001","unstructured":"Kowalski KG, Hutmacher MM (2001) Efficient screening of covariates in population models using Wald\u2019s approximation to the likelihood ratio test. J Pharmacokinet Pharmacodyn 28(3):253\u2013275","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"11","key":"3562_CR21","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1158\/1078-0432.CCR-06-2290","volume":"13","author":"JF Cote","year":"2007","unstructured":"Cote JF, Kirzin S, Kramar A, Mosnier JF, Diebold MD, Soubeyran I, Thirouard AS, Selves J, Laurent-Puig P, Ychou M (2007) UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res 13(11):3269\u20133275. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-2290","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3562_CR22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/sj.tpj.6500072","volume":"2","author":"L Iyer","year":"2002","unstructured":"Iyer L, Das S, Janisch L, Wen M, Ramirez J, Karrison T, Fleming GF, Vokes EE, Schilsky RL, Ratain MJ (2002) UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenom J 2(1):43\u201347","journal-title":"Pharmacogenom J"},{"issue":"17","key":"3562_CR23","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1093\/jnci\/djm115","volume":"99","author":"JM Hoskins","year":"2007","unstructured":"Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL (2007) UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 99(17):1290\u20131295. https:\/\/doi.org\/10.1093\/jnci\/djm115","journal-title":"J Natl Cancer Inst"},{"issue":"15","key":"3562_CR24","doi-asserted-by":"publisher","first-page":"3832","DOI":"10.1158\/1078-0432.CCR-10-1122","volume":"16","author":"ZY Hu","year":"2010","unstructured":"Hu ZY, Yu Q, Pei Q, Guo C (2010) Dose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia: low doses also increase risk. Clin Cancer Res 16(15):3832\u20133842. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-1122","journal-title":"Clin Cancer Res"},{"issue":"10","key":"3562_CR25","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1016\/j.ejca.2010.02.049","volume":"46","author":"ZY Hu","year":"2010","unstructured":"Hu ZY, Yu Q, Zhao YS (2010) Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis. Eur J Cancer 46(10):1856\u20131865. https:\/\/doi.org\/10.1016\/j.ejca.2010.02.049","journal-title":"Eur J Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-018-3562-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3562-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3562-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T22:14:50Z","timestamp":1751494490000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-018-3562-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,21]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["3562"],"URL":"https:\/\/doi.org\/10.1007\/s00280-018-3562-3","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2018,3,21]]},"assertion":[{"value":"6 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"SKBS and YC are former employees of Nektar Therapeutics; TG, UH, and MAE are employees of Nektar Therapeutics and own stocks and stock options of Nektar Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of institutional and\/or national research committees and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}